Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients.

Daniel RiggsbeeSamantha EngdahlRebecca S Pettit

Published in: Pediatric pulmonology (2023)

There was no significant increase in AKI in pediatric patients with CF receiving PZT by EI compared with TI. EI may be utilized to optimize the pharmacokinetics of PZT in pediatric CF patients.

Keyphrases

cystic fibrosis
end stage renal disease
ejection fraction
newly diagnosed
low dose
pseudomonas aeruginosa
acute kidney injury
lung function
chronic obstructive pulmonary disease